0.47
-0.0167 (-3.43%)
-0.0167 (-3.43%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
Small Cap Pro
Monthly Subscription
for only
|
|
Canna Trader Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Antibe Therapeutics Inc (QB) | ATBPF | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.0167 | -3.43% | 0.47 | 0.4649 | 0.4796 | 0.476 | 0.4867 | 16:30:01 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.40 | 0.80 | 0.40 | 50.0% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 28 | 49,166 | $ 0.474119 | $ 23,311 | 170,775 | 0.19445 - 0.5143 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:38:45 | 1,000 | $ 0.47 | USD |
Antibe Therapeutics (QB) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 135.85M | 289.03M | $ -7.43M | - | - | 240.17M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 131.99k | $ - | 0.00% | - | - |
Antibe Therapeutics (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATBPF Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.463 | 0.50481 | 0.463 | 0.4879082 | 126,220 | 0.007 | 1.51% |
| 1 Month | 0.38695 | 0.5143 | 0.3538 | 0.451877 | 264,981 | 0.08305 | 21.46% |
| 3 Months | 0.2914 | 0.5143 | 0.27775 | 0.402938 | 181,712 | 0.1786 | 61.29% |
| 6 Months | 0.29374 | 0.5143 | 0.2465 | 0.3627546 | 152,739 | 0.17626 | 60.01% |
| 1 Year | 0.207 | 0.5143 | 0.19445 | 0.3044963 | 145,074 | 0.263 | 127.05% |
| 3 Years | 0.1698 | 0.5993 | 0.0609 | 0.2797617 | 100,728 | 0.3002 | 176.8% |
| 5 Years | 0.1333 | 0.5993 | 0.0609 | 0.2768852 | 96,022 | 0.3367 | 252.59% |
Antibe Therapeutics (QB) Description
| Antibe develops safer, non-addictive medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace. |
